In summary, the modest impact of vistusertib in STK11-deficient NSCLC appears in part due to the selection of SMARCA4 co-mutated clones on treatment together with adaptive resistance driven by FOXO inactivation. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.